• NeuroSense won a Nasdaq hearing on Nov. 10, 2026, challenging an Oct. 1 staff delisting determination.
• Trading in NRSN and NRSNW continues pending a panel ruling; the $1.00 minimum bid-price rule is back in compliance.
• Remaining breach targets Nasdaq’s $35 million market-value-of-listed-securities rule; the company will seek an exception of up to 180 days.
• Plan includes steps to meet the market-value threshold or the $2.5 million stockholders’ equity alternative under Rule 5550(b)(1).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610130830PR_NEWS_USPR_____IO69666) on October 13, 2026, and is solely responsible for the information contained therein.